MedTrace Logo

Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by Smokers

NCT04640285 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-03-24

No results posted yet for this study

Summary

This study is being conducted to evaluate nicotine uptake and exposure, the abuse liability, and puffing topography associated with the use of an electronic nicotine delivery system ENDS with tobacco- and menthol-flavored e-liquids in current smokers.

Conditions

  • Electronic Cigarette Use

Interventions

OTHER

RELX ENDS Tobacco Flavor

Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

OTHER

RELX ENDS Menthol Flavor

Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions

OTHER

Usual Brand Cigarette

Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions

OTHER

Nicorette White Ice Mint nicotine polacrilex gum

Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions

Sponsors & Collaborators

  • Cheerain HK Limited

    lead INDUSTRY

Principal Investigators

  • Donald Graff, PharmD · Sponsor Representative

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
22 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-03
Primary Completion
2021-03-12
Completion
2021-03-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04640285 on ClinicalTrials.gov